BioInvent Obtains IND Approval for Clinical Trial with anti-TNFR2 Antibody BI-1910

LUND, SWEDEN / ACCESSWIRE / June 2, 2023 / BioInvent International (STO:BINV)A differentiated -agonist- approach from BI-1808, the first-in-class antibody currently in phase 1 clinical developmentPhase 1/2a study of BI-1910 as single agent and in …